Neurotrauma Sciences, LLC., a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries, including stroke and traumatic brain injury, expanded its executive management team with key appointments: Marc de Somer, chief medical officer and Martin Rabe, executive vice president of regulatory affairs and quality assurance.

de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as chief medical officer. As a therapeutic development executive with comprehensive neurological experience and critical expertise in quantitative methods/biostatistics to inform clinical design, Dr. de Somer led the development of nine novel medicines to successful global NDAs and launch. He held clinical development leadership responsibilities in Europe, the UK, and the US at Sandoz/Novartis Pharmaceuticals.

Rabe joins NeuroTrauma brings over 25 years of global drug development and regulatory expertise with biologics and small molecules focusing on neurological diseases and has helped oversee and support six new drug/biologic approvals. Most recently, Rabe served as senior vice president and head of global regulatory affairs and quality assurance for Kira Pharmaceuticals. Prior, he spent more than a decade of his career at Eisai, Inc., in senior global regulatory positions that include vice president and head of global regulatory strategy and commercial regulatory affairs neurology business group; and executive director, global regulatory affairs, where he headed the neuroscience and general medicine therapeutic areas.

“We are pleased to welcome these industry veterans to our leadership team,” said Carl Long, Ceo “Marc and Martin bring complementary records of excellence in clinical development and successful interactions with key regulatory and industry stakeholders, which will be invaluable as we prepare to initiate dosing in a Phase 1 trial of our lead program NTS-104 in stroke. We will value their leadership and direction as we advance NTS-104 through the clinic.”